ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas

AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML

Patient treatment preferences in relapsed/refractory multiple myeloma

Landscape change with oral proteasome maintenance in multiple myeloma patients

The importance of NF-kB pathway in myeloma

Multiple myeloma highlights and more from ASH 2018

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia

ASH 2018: Expert overview of the latest in CLL, ALL and AML

ECHELON-2: a large peripheral T-cell lymphoma trial

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma

Reduction of chemotherapy cycles for diffuse large B-cell lymphoma

Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy